Search

Your search keyword '"Récher, C"' showing total 324 results
Start Over Author "Récher, C"
324 results on '"Récher, C"'

5. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults

Author

Piel‐Julian, M.‐L., Mahévas, M., Germain, J., Languille, L., Comont, T., Lapeyre‐Mestre, M., Payrastre, B., Beyne‐Rauzy, O., Michel, M., Godeau, B., Adoue, D., Moulis, G., Alric, L., Arista, S., Astudillo, L., Balardy, L., Betrian, S., Bonnet, D., Borel, C., Brechemier, D., Brun, N., Carreiro, M., Castel, B., Caudrelier, L., Cougoul, P., Danu, A., Delavigne, K., Dingremont, C., Faurie, T., Gaches, F., Gaspard, M.‐H., Gaudin, C., Godel‐Labouret, A., Giraud, P., Hadj‐Khelifa, S., Hebraud, B., Khatibi, S., Leplay, L., Leveneur, Y., Limal, N., Ollier, S., Madaule, S., Marchou, B., Martel, C., Martin‐Blondel, G., Montane De La Roque, P., Michaud, M., Moeglin, J., Nuccio, F., Prudhomme, L., Pugnet, G., Recher, C., Remy, V., Sailler, L., Sire, S., Sommet, A., Tavitian, S., Thiercelin‐Legrand, M.‐F., and Vaillant, W.

Published
2018
Full Text
View/download PDF

7. High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells

Author

Poulain, L, Sujobert, P, Zylbersztejn, F, Barreau, S, Stuani, L, Lambert, M, Palama, T L, Chesnais, V, Birsen, R, Vergez, F, Farge, T, Chenevier-Gobeaux, C, Fraisse, M, Bouillaud, F, Debeissat, C, Herault, O, Récher, C, Lacombe, C, Fontenay, M, Mayeux, P, Maciel, T T, Portais, J-C, Sarry, J-E, Tamburini, J, Bouscary, D, and Chapuis, N

Published
2017
Full Text
View/download PDF

10. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma

Author

Morschhauser, F., Recher, C., Milpied, N., Gressin, R., Salles, G., Brice, P., Vey, N., Haioun, C., Colombat, P., Rossi, J.F., Deconinck, E., Lazreg, F., Bergougnoux, L., Delsol, G., and Attal, M.

Published
2012
Full Text
View/download PDF

12. P421: LOWER VΓ9VΔ2 T CELLS RELATIVE FREQUENCIES PREDICT POORER SURVIVAL IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

Author

Le Floch, A.-C., primary, Orlanducci, F., additional, Le Roy, A., additional, Hamel, J.-F., additional, Ifrah, N., additional, Cornillet-Lefebvre, P., additional, Delaunay, J., additional, Récher, C., additional, Delabesse, E., additional, Pigneux, A., additional, Béné, M.-C., additional, Vey, N., additional, Chretien, A.-S., additional, and Olive, D., additional

Published
2022
Full Text
View/download PDF

14. Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights

Author

Martin, J.E., Khalife-Hachem, S., Grinda, T., Kfoury, M., Garciaz, S., Pasquier, F., Vargaftig, J., Uzunov, M., Belhabri, A., Bertoli, S., Cotteret, S., Vergé, V., Renneville, A., Rosselli, F., Antony-Debre, I., Rouleau, E., Salviat, F., Caron, O., Delaloge, S., Pautier, P., Etienne, G., Recher, C., Vey, N., De Botton, S., Leary, A., Marzac, C., and Micol, J.B.

Published
2021
Full Text
View/download PDF

19. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)

Author

Dupont, H., Marolleau, J.P., Totet, A., Damiani, C., Berceanu, A., Larosa, F., Bonhomme, J., Chabrot, C., Bouteille, B., Boutoille, D., Gastinne, T., Peterlin, P., Gari Toussaint, M., Poisson, D., Briet, D., Buret, J., Legrand, M., Denis, B., Raffoux, E., Bergeron, A., Veinstein, A., Godet, C., N'guyen, Y., Diallo, S., Sabou, M., Denis, J., Ledoux, M.P., Recher, C., Ruiz, J., Desoubeaux, G., Bailly, E., Chachaty, E., Dromer, F., Lortholary, O., Sitbon, K., Hoinard, D., Millon, L., Herbrecht, R., Grenouillet, F., Morio, F., Alanio, A., Letscher-Bru, V., Cassaing, S., Chouaki, T., Kauffmann-Lacroix, C., Poirier, P., Toubas, D., Augereau, O., Rocchi, S., Garcia-Hermoso, D., and Bretagne, S.

Published
2016
Full Text
View/download PDF

23. L’ajout de la lomustine bénéficie aux leucémies myéloïdes aiguës du sujet âgé avec cytogénétique non-défavorable et d’un profil moléculaire à haut risque de l’European Leukemia Net 2017

Author

Largeaud, L., Cornillet-Lefebvre, P., Hamel, J.F., Dumas, P.Y., Prade, N., Dufrechou, S., Plenecassagnes, J., Luquet, I., Blanchet, O., Banos, A., Bene, M.C., Bernard, M., Bertoli, S., Bonmati, C., FORNECKER, L.M., Guièze, R., Hicheri, Y., Hunault-Berger, M., Ianotto, J.C., Jourdan, E., Ojeda-Uribe, M., Peterlin, P., Vey, N., Zerazhi, H., Mineur, A., Cahn, J.Y., Ifrah, N., Récher, C., Pigneux, A., Delabesse, E., Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), and Université Clermont Auvergne [2017-2020] (UCA [2017-2020])

Subjects
[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology
Abstract

07-03; International audience

Published
2020

25. Inflammation regulates long non-coding RNA-PTTG1-1:1 in myeloid leukemia

Author

Chateauvieux, S., Gaigneaux, Anthoula, Gerard, Déborah, Orsini, M., Morceau, F., Orlikova-Boyer, B., Farge, T., Récher, C., Sarry, J.-E., Dicato, M., Diederich, M., Chateauvieux, S., Gaigneaux, Anthoula, Gerard, Déborah, Orsini, M., Morceau, F., Orlikova-Boyer, B., Farge, T., Récher, C., Sarry, J.-E., Dicato, M., and Diederich, M.

Abstract

[No abstract available]

Published
2020

35. Etude de l'effet du centre de traitement sur l'adhésion au plan de traitement dans le lymphome B diffus à grandes cellules : une analyse multiniveau d'une cohorte observationnelle en région Midi-Pyrénées en onco-hématologie

Author

Lamy, S, Albertus, G, Grosclaude, Pascale, Bettiol, C, Compaci, G, Récher, C, Nogaro, JC, Despas, F, LAURENT, G, Delpierre, C, Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2016

36. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia

Author

Hospital, M-A, primary, Jacquel, A, additional, Mazed, F, additional, Saland, E, additional, Larrue, C, additional, Mondesir, J, additional, Birsen, R, additional, Green, A S, additional, Lambert, M, additional, Sujobert, P, additional, Gautier, E-F, additional, Salnot, V, additional, Le Gall, M, additional, Decroocq, J, additional, Poulain, L, additional, Jacque, N, additional, Fontenay, M, additional, Kosmider, O, additional, Récher, C, additional, Auberger, P, additional, Mayeux, P, additional, Bouscary, D, additional, Sarry, J-E, additional, and Tamburini, J, additional

Published
2017
Full Text
View/download PDF

37. A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia

Author

Saland, E, Boutzen, H, Castellano, R, Pouyet, L, Griessinger, E, Larrue, C, de Toni, F, Scotland, S, David, Mathieu, Danet-Desnoyers, G, Vergez, F, Barreira, Y, Collette, Yves, Récher, C, Sarry, J-E, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), IUT de Tarbes, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Medicine, Perelman School of Medicine, University of Pennsylvania [Philadelphia]-University of Pennsylvania [Philadelphia], Service d'Expérimentation Animale, UMS006, CHU Toulouse [Toulouse], Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Toulouse (UT)-Université de Toulouse (UT), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), University of Pennsylvania-University of Pennsylvania, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), and HAL AMU, Administrateur

Subjects
BUSULFAN, ENGRAFTMENT, [SDV.CAN] Life Sciences [q-bio]/Cancer, NOD/SCID MICE, TRANSPLANTATION, hemic and lymphatic diseases, IMMUNODEFICIENT MICE, CELLS, [SDV.CAN]Life Sciences [q-bio]/Cancer, HEMATOPOIESIS, neoplasms, IRRADIATION
Abstract

International audience; Relevant preclinical mouse models are crucial to screen new therapeutic agents for acute myeloid leukemia (AML). Current in vivo models based on the use of patient samples are not easy to establish and manipulate in the laboratory. Our objective was to develop robust xenograft models of human AML using well-characterized cell lines as a more accessible and faster alternative to those incorporating the use of patient-derived AML cells. Five widely used AML cell lines representing various AML subtypes were transplanted and expanded into highly immunodeficient non-obese diabetic/LtSz-severe combined immunodeficiency IL2R gamma(null)(c) mice (for example, cell line-derived xenografts). We show here that bone marrow sublethal conditioning with busulfan or irradiation has equal efficiency for the xenotransplantation of AML cell lines. Although higher number of injected AML cells did not change tumor engraftment in bone marrow and spleen, it significantly reduced the overall survival in mice for all tested AML cell lines. On the basis of AML cell characteristics, these models also exhibited a broad range of overall mouse survival, engraftment, tissue infiltration and aggressiveness. Thus, we have established a robust, rapid and straightforward in vivo model based on engraftment behavior of AML cell lines, all vital prerequisites for testing new therapeutic agents in preclinical studies.

Published
2015
Full Text
View/download PDF

40. Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia

Author

Cerella, C, primary, Gaigneaux, A, additional, Mazumder, A, additional, Lee, J-Y, additional, Saland, E, additional, Radogna, F, additional, Farge, T, additional, Vergez, F, additional, Récher, C, additional, Sarry, J-E, additional, Kim, K-W, additional, Shin, H Y, additional, Dicato, M, additional, and Diederich, M, additional

Published
2016
Full Text
View/download PDF

43. Étude de l’effet du centre de traitement sur l’adhésion au plan de traitement dans le lymphome B diffus à grandes cellules : une analyse multiniveau d’une cohorte observationnelle en région Midi-Pyrénées en onco-hématologie

Author

Lamy, S., primary, Albertus, G., additional, Grosclaude, P., additional, Bettiol, C., additional, Compaci, G., additional, Récher, C., additional, Nogaro, J.-C., additional, Despas, F., additional, Laurent, G., additional, and Delpierre, C., additional

Published
2016
Full Text
View/download PDF

44. 124 AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY

Author

Seymour, J.F., primary, Döhner, H., additional, Butrym, A., additional, Wierzbowska, A., additional, Selleslag, D., additional, Jang, J.H., additional, Cavenagh, J.D., additional, Kumar, R., additional, Schuh, A.C., additional, Candoni, A., additional, Récher, C., additional, Sandhu, I., additional, del Castillo, T. Bernal, additional, Al-Ali, H.K., additional, Martinelli, G., additional, Falantes, J., additional, Nopenney, R., additional, Stone, R.M., additional, Minden, M.D., additional, McIntyre, H., additional, Songer, S., additional, Lucy, L.M., additional, Beach, C.L., additional, and Dombret, H., additional

Published
2015
Full Text
View/download PDF

45. 96 OVERALL SURVIVAL IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML WITH >30% BONE MARROW BLASTS AND POOR-RISK CYTOGENETICS TREATED WITH AZACITIDINE: SUBANALYSIS OF THE AZA-AML-001 STUDY

Author

Döhner, H., primary, Seymour, J.F., additional, Butrym, A., additional, Wierzbowska, A., additional, Selleslag, D., additional, Jang, J.H., additional, Cavenagh, J.D., additional, Kumar, R., additional, Schuh, A.C., additional, Candoni, A., additional, Récher, C., additional, Sandhu, I., additional, del Castillo, T. Bernal, additional, Al-Ali, H.K., additional, Martinelli, G., additional, Falantes, J., additional, Nopenney, R., additional, Stone, R.M., additional, Minden, M.D., additional, McIntyre, H., additional, Songer, S., additional, Lucy, L.M., additional, Beach, C.L., additional, and Dombret, H., additional

Published
2015
Full Text
View/download PDF

46. Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorder

Author

Poulain, L., Sujobert, P., Zylbersztejn, F., Barreau, S., Lambert, M., Chesnais, V., Birsen, R, Vergez, F., Farge, T., Chenevier-Gobeaux, C., Fraisse, M., Bouillaud, F., Debeissat, C., Herault, O., Récher, C., Lacombe, C., Fontenay, M., Mayeux, P., Maciel, T. T., Sarry, J.E., Tamburini, J., Bouscary, D., Chapuis, N., Laboratoire psychologie de la perception (LPP), Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Descartes - Paris 5 (UPD5)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES), Yale University [New Haven], Récepteurs stéroïdiens : physiopathologie endocrinienne et métabolique, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR93-Université Paris-Sud - Paris 11 (UP11), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre Emotion, Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de psychologie cognitive (LPC), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Génétique Médicale et Génomique Fonctionnelle (GMGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université - Faculté de médecine (AMU MED), Aix Marseille Université (AMU), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Ligue Nationale Contre le Cancer - Paris, Ligue Nationale Contre le Cancer (LNCC), Université Sorbonne Paris Cité (USPC), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Ingénierie des Systèmes Biologiques et des Procédés (LISBP), Institut National de la Recherche Agronomique (INRA)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), UMR1037, Cancer Research Center of Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpitaux Universitaires Paris Centre, Service de Diagnostic Biologique Automatisé, Assistance Publique - Hôpitaux de Paris, Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Institut Cochin (UMR_S567 / UMR 8104), Equipe Labellisée, Hôpitaux Universitaires Paris Centre, Service d'Hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université de Rennes (UR), Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Ligue Nationnale Contre le Cancer, Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Ligue Nationale Contre le Cancer, Pérez-Diaz, Fernando, Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Recherche Agronomique (INRA), Université de Tours-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), and Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, medicine.medical_specialty, Adolescent, Pain, lcsh:Medicine, Biology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, Internal medicine, Heart rate, mental disorders, medicine, Humans, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Autistic Disorder, Reactivity (psychology), Psychiatry, Child, lcsh:Science, 030304 developmental biology, 0303 health sciences, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, Multidisciplinary, Venipuncture, beta-Endorphin, lcsh:R, Case-control study, Genetics and Genomics/Gene Expression, medicine.disease, Mental Health/Child and Adolescent Psychiatry, Mental Health, Opioid, chemistry, Case-Control Studies, Autism, Female, lcsh:Q, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], 030217 neurology & neurosurgery, medicine.drug, Blood drawing, Research Article
Abstract

International audience; Background: Reports of reduced pain sensitivity in autism have prompted opioid theories of autism and have practical care ramifications. Our objective was to examine behavioral and physiological pain responses, plasma β-endorphin levels and their relationship in a large group of individuals with autism.Methodology/Principal Findings: The study was conducted on 73 children and adolescents with autism and 115 normal individuals matched for age, sex and pubertal stage. Behavioral pain reactivity of individuals with autism was assessed in three observational situations (parents at home, two caregivers at day-care, a nurse and child psychiatrist during blood drawing), and compared to controls during venepuncture. Plasma β-endorphin concentrations were measured by radioimmunoassay. A high proportion of individuals with autism displayed absent or reduced behavioral pain reactivity at home (68.6%), at day-care (34.2%) and during venepuncture (55.6%). Despite their high rate of absent behavioral pain reactivity during venepuncture (41.3 vs. 8.7% of controls, P

Published
2009
Full Text
View/download PDF

47. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia

Author

Hospital, M-A, Jacquel, A, Mazed, F, Saland, E, Larrue, C, Mondesir, J, Birsen, R, Green, A S, Lambert, M, Sujobert, P, Gautier, E-F, Salnot, V, Le Gall, M, Decroocq, J, Poulain, L, Jacque, N, Fontenay, M, Kosmider, O, Récher, C, Auberger, P, Mayeux, P, Bouscary, D, Sarry, J-E, and Tamburini, J

Abstract

Acute myeloid leukemia (AML) with the FLT3 internal tandem duplication (FLT3-ITD AML) accounts for 20–30% of AML cases. This subtype usually responds poorly to conventional therapies, and might become resistant to FLT3 tyrosine kinase inhibitors (TKIs) due to molecular bypass mechanisms. New therapeutic strategies focusing on resistance mechanisms are therefore urgently needed. Pim kinases are FLT3-ITD oncogenic targets that have been implicated in FLT3 TKI resistance. However, their precise biological function downstream of FLT3-ITD requires further investigation. We performed high-throughput transcriptomic and proteomic analyses in Pim2-depleted FLT3-ITD AML cells and found that Pim2 predominantly controlled apoptosis through Bax expression and mitochondria disruption. We identified ribosomal protein S6 kinase A3 (RSK2), a 90?kDa serine/threonine kinase involved in the mitogen-activated protein kinase cascade encoded by the RPS6KA3 gene, as a novel Pim2 target. Ectopic expression of an RPS6KA3 allele rescued the viability of Pim2-depleted cells, supporting the involvement of RSK2 in AML cell survival downstream of Pim2. Finally, we showed that RPS6KA3 knockdown reduced the propagation of human AML cells in vivo in mice. Our results point to RSK2 as a novel Pim2 target with translational therapeutic potential in FLT3-ITD AML.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results